BACKGROUND: Leprosy is complicated by immunological reactions which can occur before, during and after successful completion of multidrug therapy. Genetic studies have suggested that polymorphisms in toll-like receptors (TLRs) may affect the susceptibility of an individual with leprosy to developing Type 1 reactions. OBJECTIVES: To examine the gene and protein expression of TLRs in the cutaneous lesions of leprosy Type 1 reactions at the onset of reaction and during systemic corticosteroid therapy. METHODS:Patients who were being treated for leprosy type 1 reactions withcorticosteroids as part of a randomized controlled trial of corticosteroid treatment had skin biopsies performed before, during and at the end of treatment. The gene and protein expression of TLR2 and TLR4 were measured. RESULTS: We have demonstrated that the gene hARP-P0 is a suitable control gene for TLR gene expression studies in this population. The gene and protein expression of TLR2 and TLR4 were both reduced significantly during corticosteroid treatment. CONCLUSIONS: This is the first study to examine the expression of TLR2 and TLR4 in vivo in individuals experiencing leprosy Type 1 reactions. The data support the possibility of an important role for TLR2 and TLR4 in the pathogenesis of this important complication of leprosy.
RCT Entities:
BACKGROUND:Leprosy is complicated by immunological reactions which can occur before, during and after successful completion of multidrug therapy. Genetic studies have suggested that polymorphisms in toll-like receptors (TLRs) may affect the susceptibility of an individual with leprosy to developing Type 1 reactions. OBJECTIVES: To examine the gene and protein expression of TLRs in the cutaneous lesions of leprosy Type 1 reactions at the onset of reaction and during systemic corticosteroid therapy. METHODS:Patients who were being treated for leprosy type 1 reactions with corticosteroids as part of a randomized controlled trial of corticosteroid treatment had skin biopsies performed before, during and at the end of treatment. The gene and protein expression of TLR2 and TLR4 were measured. RESULTS: We have demonstrated that the gene hARP-P0 is a suitable control gene for TLR gene expression studies in this population. The gene and protein expression of TLR2 and TLR4 were both reduced significantly during corticosteroid treatment. CONCLUSIONS: This is the first study to examine the expression of TLR2 and TLR4 in vivo in individuals experiencing leprosy Type 1 reactions. The data support the possibility of an important role for TLR2 and TLR4 in the pathogenesis of this important complication of leprosy.
Authors: Gi S Yoon; Sudha Sud; Rahul K Keswani; Jason Baik; Theodore J Standiford; Kathleen A Stringer; Gus R Rosania Journal: Mol Pharm Date: 2015-06-05 Impact factor: 4.939
Authors: Mayara Garcia de Mattos Barbosa; Bruno Jorge de Andrade Silva; Tayná Quintella Assis; Rhana Berto da Silva Prata; Helen Ferreira; Priscila Ribeiro Andrade; Jéssica Araújo da Paixão de Oliveira; Gilberto Marcelo Sperandio da Silva; José Augusto da Costa Nery; Euzenir Nunes Sarno; Roberta Olmo Pinheiro Journal: Front Immunol Date: 2018-06-04 Impact factor: 7.561
Authors: Anastasia Polycarpou; Martin J Holland; Ioannis Karageorgiou; Ayad Eddaoudi; Stephen L Walker; Sam Willcocks; Diana N J Lockwood Journal: Front Cell Infect Microbiol Date: 2016-07-08 Impact factor: 5.293
Authors: Roberta Olmo Pinheiro; Veronica Schmitz; Bruno Jorge de Andrade Silva; André Alves Dias; Beatriz Junqueira de Souza; Mayara Garcia de Mattos Barbosa; Danuza de Almeida Esquenazi; Maria Cristina Vidal Pessolani; Euzenir Nunes Sarno Journal: Front Immunol Date: 2018-03-28 Impact factor: 7.561